Burning Rock Biotech Limited (BNR)
NASDAQ: BNR · Real-Time Price · USD
5.67
-0.09 (-1.56%)
At close: Aug 1, 2025, 4:00 PM
5.73
+0.06 (1.06%)
After-hours: Aug 1, 2025, 7:50 PM EDT

Company Description

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States.

It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.

The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers.

The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products.

In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA.

Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Burning Rock Biotech Limited
Burning Rock Biotech logo
CountryChina
Founded2014
IPO DateJun 12, 2020
IndustryDiagnostics & Research
SectorHealthcare
Employees674
CEOYusheng Han

Contact Details

Address:
No. 5, Xingdao Ring Road North, International Bio Island
Guangzhou, 510005
China
Phone86 20 3403 7871
Websitebrbiotech.com

Stock Details

Ticker SymbolBNR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyCNY
IPO Price$16.50
CIK Code0001792267
CUSIP Number12233L107
ISIN NumberUS12233L2060
SIC Code8071

Key Executives

NamePosition
Yusheng HanFounder, Chairman and Chief Executive Officer
Xiaozhi HuSenior Director of Finance
Dr. Zhihong ZhangChief Technology Officer and Director
Hao LiuSenior Advisor

Latest SEC Filings

DateTypeTitle
Jun 6, 20256-KReport of foreign issuer
Apr 29, 202520-FAnnual and transition report of foreign private issuers
Mar 25, 20256-KReport of foreign issuer
Dec 31, 20246-KReport of foreign issuer
Dec 4, 20246-KReport of foreign issuer
Dec 3, 20246-KReport of foreign issuer
Nov 27, 2024UPLOADFiling
Nov 26, 202420-F/AFiling
Nov 14, 2024SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
Oct 31, 2024UPLOADFiling